Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Aug 1;98(3):622–628. doi: 10.1172/JCI118832

Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.

C Perreault 1, J Jutras 1, D C Roy 1, J G Filep 1, S Brochu 1
PMCID: PMC507470  PMID: 8698852

Abstract

T cell responses to non-MHC antigens are targeted to a restricted number of immunodominant minor histocompatibility antigens whose identity remains elusive. Here we report isolation and sequencing of a novel immunodominant minor histocompatibility antigen presented by H-2Db on the surface of C57BL/6 mouse cells. This nonapeptide (AAPDNRETF) shows strong biologic activity in cytotoxic T lymphocyte sensitization assays at concentrations as low as 10 pM. C3H.SW mice primed with AAPDNRETF in incomplete Freund's adjuvant generated a potent anti-C57BL/6 T cell-mediated cytotoxic activity, and T lymphocytes from AAPDNRETF-primed mice caused graft-versus-host disease when transplanted in irradiated C57BL/6 recipients. These results (a) provide molecular characterization of a mouse dominant minor histocompatibility antigen, (b) identify this peptide as a potential target of graft-versus-host disease and, (c) more importantly, demonstrate that a single dominant minor antigen can cause graft-versus-host disease. These findings open new avenues for the prevention of graft-versus-host disease and should further our understanding of the mechanisms of immunodominance in T cell responses to minor histocompatibility antigens.

Full Text

The Full Text of this article is available as a PDF (224.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aichele P., Brduscha-Riem K., Zinkernagel R. M., Hengartner H., Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med. 1995 Jul 1;182(1):261–266. doi: 10.1084/jem.182.1.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ashton-Rickardt P. G., Bandeira A., Delaney J. R., Van Kaer L., Pircher H. P., Zinkernagel R. M., Tonegawa S. Evidence for a differential avidity model of T cell selection in the thymus. Cell. 1994 Feb 25;76(4):651–663. doi: 10.1016/0092-8674(94)90505-3. [DOI] [PubMed] [Google Scholar]
  3. Brochu S., Baron C., Hétu F., Roy D. C., Perreault C. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras. J Immunol. 1995 Dec 1;155(11):5104–5114. [PubMed] [Google Scholar]
  4. Chen W., Khilko S., Fecondo J., Margulies D. H., McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med. 1994 Oct 1;180(4):1471–1483. doi: 10.1084/jem.180.4.1471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Correa I., Raulet D. H. Binding of diverse peptides to MHC class I molecules inhibits target cell lysis by activated natural killer cells. Immunity. 1995 Jan;2(1):61–71. doi: 10.1016/1074-7613(95)90079-9. [DOI] [PubMed] [Google Scholar]
  6. Dyall R., Vasović L. V., Molano A., Nikolić-Zugić J. CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Int Immunol. 1995 Aug;7(8):1205–1212. doi: 10.1093/intimm/7.8.1205. [DOI] [PubMed] [Google Scholar]
  7. Feltkamp M. C., Vreugdenhil G. R., Vierboom M. P., Ras E., van der Burg S. H., ter Schegget J., Melief C. J., Kast W. M. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol. 1995 Sep;25(9):2638–2642. doi: 10.1002/eji.1830250935. [DOI] [PubMed] [Google Scholar]
  8. Ferrara J. L., Deeg H. J. Graft-versus-host disease. N Engl J Med. 1991 Mar 7;324(10):667–674. doi: 10.1056/NEJM199103073241005. [DOI] [PubMed] [Google Scholar]
  9. Fontaine P., Langlais J., Perreault C. Evaluation of in vitro cytotoxic T lymphocyte assays as a predictive test for the occurrence of graft vs host disease. Immunogenetics. 1991;34(4):222–226. doi: 10.1007/BF00215256. [DOI] [PubMed] [Google Scholar]
  10. Franksson L., Petersson M., Kiessling R., Kärre K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol. 1993 Oct;23(10):2606–2613. doi: 10.1002/eji.1830231034. [DOI] [PubMed] [Google Scholar]
  11. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J. H., Vossen J., Gratwohl A., Vogelsang G. B., van Houwelingen H. C., van Rood J. J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996 Feb 1;334(5):281–285. doi: 10.1056/NEJM199602013340501. [DOI] [PubMed] [Google Scholar]
  12. Jorgensen J. L., Esser U., Fazekas de St Groth B., Reay P. A., Davis M. M. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. Nature. 1992 Jan 16;355(6357):224–230. doi: 10.1038/355224a0. [DOI] [PubMed] [Google Scholar]
  13. Korngold R. Pathophysiology of graft-versus-host disease directed to minor histocompatibility antigens. Bone Marrow Transplant. 1991;7 (Suppl 1):38–41. [PubMed] [Google Scholar]
  14. Korngold R., Wettstein P. J. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens. J Immunol. 1990 Dec 15;145(12):4079–4088. [PubMed] [Google Scholar]
  15. Loveland B., Wang C. R., Yonekawa H., Hermel E., Lindahl K. F. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. Cell. 1990 Mar 23;60(6):971–980. doi: 10.1016/0092-8674(90)90345-f. [DOI] [PubMed] [Google Scholar]
  16. Malnati M. S., Peruzzi M., Parker K. C., Biddison W. E., Ciccone E., Moretta A., Long E. O. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science. 1995 Feb 17;267(5200):1016–1018. doi: 10.1126/science.7863326. [DOI] [PubMed] [Google Scholar]
  17. Martin P. J. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant. 1991 Sep;8(3):217–223. [PubMed] [Google Scholar]
  18. Miconnet I., de la Selle V., Tucek C., Huchet R., Bonardelle D., Bruley-Rosset M. Tissue distribution and polymorphism of minor histocompatibility antigens involved in GVHR. Immunogenetics. 1994;39(3):178–186. doi: 10.1007/BF00241258. [DOI] [PubMed] [Google Scholar]
  19. Morse M. C., Bleau G., Dabhi V. M., Hétu F., Drobetsky E. A., Lindahl K. F., Perreault C. The COI mitochondrial gene encodes a minor histocompatibility antigen presented by H2-M3. J Immunol. 1996 May 1;156(9):3301–3307. [PubMed] [Google Scholar]
  20. Perreault C., Décary F., Brochu S., Gyger M., Bélanger R., Roy D. Minor histocompatibility antigens. Blood. 1990 Oct 1;76(7):1269–1280. [PubMed] [Google Scholar]
  21. Pion S., Fontaine P., Baron C., Gyger M., Perreault C. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest. 1995 Apr;95(4):1561–1568. doi: 10.1172/JCI117829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rammensee H. G., Falk K., Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 1993;11:213–244. doi: 10.1146/annurev.iy.11.040193.001241. [DOI] [PubMed] [Google Scholar]
  23. Rammensee H. G., Friede T., Stevanoviíc S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41(4):178–228. doi: 10.1007/BF00172063. [DOI] [PubMed] [Google Scholar]
  24. Rudensky AYu, Preston-Hurlburt P., Hong S. C., Barlow A., Janeway C. A., Jr Sequence analysis of peptides bound to MHC class II molecules. Nature. 1991 Oct 17;353(6345):622–627. doi: 10.1038/353622a0. [DOI] [PubMed] [Google Scholar]
  25. Scott D. M., Ehrmann I. E., Ellis P. S., Bishop C. E., Agulnik A. I., Simpson E., Mitchell M. J. Identification of a mouse male-specific transplantation antigen, H-Y. Nature. 1995 Aug 24;376(6542):695–698. doi: 10.1038/376695a0. [DOI] [PubMed] [Google Scholar]
  26. Sebzda E., Wallace V. A., Mayer J., Yeung R. S., Mak T. W., Ohashi P. S. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science. 1994 Mar 18;263(5153):1615–1618. doi: 10.1126/science.8128249. [DOI] [PubMed] [Google Scholar]
  27. Storkus W. J., Zeh H. J., 3rd, Salter R. D., Lotze M. T. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):94–103. [PubMed] [Google Scholar]
  28. Takahashi H., Nakagawa Y., Leggatt G. R., Ishida Y., Saito T., Yokomuro K., Berzofsky J. A. Inactivation of human immunodeficiency virus (HIV)-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism? J Exp Med. 1996 Mar 1;183(3):879–889. doi: 10.1084/jem.183.3.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Takeshita T., Takahashi H., Kozlowski S., Ahlers J. D., Pendleton C. D., Moore R. L., Nakagawa Y., Yokomuro K., Fox B. S., Margulies D. H. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J Immunol. 1995 Feb 15;154(4):1973–1986. [PubMed] [Google Scholar]
  30. Wallny H. J., Rammensee H. G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature. 1990 Jan 18;343(6255):275–278. doi: 10.1038/343275a0. [DOI] [PubMed] [Google Scholar]
  31. Wang W., Meadows L. R., den Haan J. M., Sherman N. E., Chen Y., Blokland E., Shabanowitz J., Agulnik A. I., Hendrickson R. C., Bishop C. E. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995 Sep 15;269(5230):1588–1590. doi: 10.1126/science.7667640. [DOI] [PubMed] [Google Scholar]
  32. Wei M. L., Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992 Apr 2;356(6368):443–446. doi: 10.1038/356443a0. [DOI] [PubMed] [Google Scholar]
  33. Wettstein P. J. Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics. 1986;24(1):24–31. doi: 10.1007/BF00372294. [DOI] [PubMed] [Google Scholar]
  34. Yin L., Poirier G., Neth O., Hsuan J. J., Totty N. F., Stauss H. J. Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens. Int Immunol. 1993 Sep;5(9):1003–1009. doi: 10.1093/intimm/5.9.1003. [DOI] [PubMed] [Google Scholar]
  35. Young A. C., Zhang W., Sacchettini J. C., Nathenson S. G. The three-dimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection. Cell. 1994 Jan 14;76(1):39–50. doi: 10.1016/0092-8674(94)90171-6. [DOI] [PubMed] [Google Scholar]
  36. den Haan J. M., Sherman N. E., Blokland E., Huczko E., Koning F., Drijfhout J. W., Skipper J., Shabanowitz J., Hunt D. F., Engelhard V. H. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995 Jun 9;268(5216):1476–1480. doi: 10.1126/science.7539551. [DOI] [PubMed] [Google Scholar]
  37. van Els C. A., Bakker A., Zwinderman A. H., Zwaan F. E., van Rood J. J., Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation. 1990 Jul;50(1):62–66. doi: 10.1097/00007890-199007000-00011. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES